| More

Oestrogen receptors and antioestrogen treatment of hormone-dependent tumours

Views: 73 Downloads: 68
N. G. KOSTOMITSOPOULOS (Ν.Γ. ΚΩΣΤΟΜΗΤΣΟΠΟΥΛΟΣ)
N. G. KOSTOMITSOPOULOS (Ν.Γ. ΚΩΣΤΟΜΗΤΣΟΠΟΥΛΟΣ)

Abstract


The oestrogen receptor is a ligand-activated transcription factor that modulates specific gene expression by binding to short DNA sequences. The study of the role of oestrogen receptor on the expression of the mitogenic actionof oestrogens and oncogenesis lead biomedical research in new approaches of the treatment of oestrogen-dependent tumors by using antioestrogens. Main mechanism of action of antioestrogens is the prevention of oestrogen action by blocking the binding of oestradiol to the oestrogen receptor. Tamoxifen, the most wellknown antioestrogen, is widely used as adjuvant therapy in all stages of human breast cancer. Recently interest is focused on the potential use of "pure" antioestrogens. The use of antioestrogens in veterinary oncology is also under discussion.


Keywords


οιστρογονικοί υποδοχείς; αντιοιστρογόνα; ταμοξιφαίνη

Full Text:

PDF

References


Beatson GT. On the treatment of inoperable cases in carcinoma of the mamma: suggestion for new method of treatment illustrative cases. Lancet 1896, 2:104-107

…………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………

Powcis Ti, Jones Ai., Ashley SE, O'Brien MER, Tid> VA, Treieavên J, Cosgrove D, Nash AG. Sacks N, Baum McKinna JA. DaveyJB. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer ResTreal 1994,31:73-82

Robertson DW, Katzenellenbogen JA, Long DJ, Roi : Katzenellenbogen BS. Tamoxifen antiestrogen. A comparison of the activity, pharmacokinetics and metabolic activation of the eis- and trans- isomers of tamoxifen, J Steroid Biochem 1982, 16:1-13

Rochefort H, Borgna JL, Evans E. Cellular and molecular mechanism of action of antiestrogens. J Steroid Biochem 1983, 19:69-74

Morris JS, Dobson JM. BostóckDE. Use of t amoxi fen in the control of canine mammary neoplasia. Vet Ree 1993, 133:539-542

Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev 1984, 36:245-275

Ruben J. Use of tamoxifen in control of canine mammary neoplasia. Vet Ree 1993, 133:602

Baker RW. Use of tamoxifen in the control of canine mammary neoplasia. Vet Ree 1994, 134:2 !

Hemminki K, Widlak P, Hon SM. DNA adducis caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Carcinogenesis 1995,16:1661-1664

Osborne CK. Mechanisms of tamoxifen resistance in breast cancer: possible role of tamoxifen metabolism J Steroid Biochem Molec Biol 1993,47:83-89

DeCupis A, Nooman D, Pirani P, Ferrera A, Clerico L, Favoni RE. Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-1-induced proliferation of human breast cancer-derived ceils. Br J Pharmacol L995J 16:2391-2400

Jordan VC. Molecular mechanisms of antiestogen action in breast cancer. Breast Cancer Res Treat 1994,31:41 -52

Toft D, Shyamala Ci, Gorski J. A receptor molecu estrogens: studies using a cell-free system. Proc Natl Acad Sci USA 1967,57:1740-1743

Skidmore JR, Walpole AL. Woodburn J. Effect oï some triphenyieihylenes on estradiol binding in Miro to maeromolecules from uterus and anterior pituitary, J

Endocrinol 1972,52:289 . 98

Binari Ν, Catelli ΜΗ, Greynot C, Pun V, Hehnei R. Mester J, Baulieu EE. Monohydroxy-tamoxifen: an antiestr« •••_.• n w il :ί high affinity for the chick oviduct estrogen receptor. Biochem Biophys Res Commun 1979, 91 :S 12-818

Croxtail JD, Emmas C, White JO, Choudhary Q Flave! $}. Tamoxifen inhibits growth oi estrogen receptor-negative A549 cells. Biochem Pharmacol 1W. 47:197-202

Daniel CP, Gaskeil SJ, Nicholson Rl. The measurement of tamoxifen and metabolites in die rat and relationship to the response of DMBA-induced mammary tumours Eui J Cancer Clin Oncol 1984, 20:137-143

Sunderland MC, Osborne CK. Tamoxifen in premenopausal patient with metastatic breast cancer: a review. J < 1991,7:1283-1297

Robinson SP, Jordan VC. Reversal of antitumor effects of tamoxifen by progesterone in the 7,12-dimethylbenzanthracene- induced rat mammary carcinoma model. Cancer Res 1987,47:5386-5390

Jordan VC, Gottardis MM, Robinson SP, Field A. Immune deficient animals to study "hormone-dependent" breast cancer and endometrial cancer. J Steroid Biochem 1989, 34:169-176

Kon OL. An antiestrogen-binding protein in human tissues. J BiolChem 1983,258:3173-3177

Musgrove EA, Wakeling AE, Sutherland RL. Points ofestrogen antagonists and a calmodulin antagonist within MCF-7 human breast cancer cell cycle. Cancer Res 1989, 49:2398-2404

Kroeger EA, Brandes LJ. Evidence that tamoxifen is an histamine antagonist. Biochem Biophys Res Commun 1985, 131:750-755

Tavares IA, Stamford IF, Bennet A. Tamoxifen inhibits 5-lipoxygenase in human polymorphonuclear lymphocytes. J Pharm Pharmacol 1987, 39:323-324

O'Brien CA, Liskamp RM, Solomon DH, Weinstein IB. Triphenylethylenes: a new class of protein kinase C inhibitors. J Natl Cancer Inst 1986, 76:1243-1246

Mandeville R, Ghali SS, Chausseau JP. In vitro stimulation of human NK activity by an estrogen antagonist (tamoxifen). Eur J Cancer Clin Oncol 1984, 20:983-985

Roche ion H, Lign α F. < apon F. Formation of estrogen nuclear receptor in the uterus: effect of androgens, estrone and nafoxidine. Biochem Biophys Res Commun 1972, 47:662-670

Clark JH. Anderson JN, Peck EJ. Estrogen receptorantiestrogen complex: atypical binding by uterine nuclei and effects on uterine growth, steroids 1973,22:707-718

Pavlik EJ, Nelson K. van Nagel! JRJr. Donaldson ES, Waiden ML. Hanson MB. Gallion H, Flanigan RC, Kenady DE. Hydrodynamic characterization of estrogen receptor complexes with [lH)-4-hydroxytamoxifen: evidence in support of contrasting receptor transitions mediated by different ligands. Biochemistry 1985.24:8101-8106

Pavlik EJ, von Nagell JRJr. Nelson K, Gallion H, Donaldson ES, Kenady DE. Baranowska-Kortylewicz J. Antagonism to estradiol in the mouse: reduced entry of receptors complexed with 4-hydroxytamoxifen into a Mg, : -soluble chromatin fraction. Endocrinology 1986, 118:1924-1934

Metzger D, White JH, Chambon P. The human oestrogen receptor functions in yeast. Nature 1988,334:31-36

Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonist activity of the antiestrogen 4-hydroxytamoxifen. EMBO J 1990,9:2811-2818

Wakeling AE. Are breast tumours resistant to tamoxifen also resistant to pure antiestrogens? J Steroid Biochem Molec Biol 1993,47:107-114


Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 NG KOSTOMITSOPOULOS

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.